NCT01875237 · OUTCOME

To Evaluate the Safety of Donor Lymphocyte Infusion Followed by Dimerizer Drug, AP1903 by Number of Participants With Adverse Events.

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene · Source last updated 2019-07-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: up to 3.5 years

What was measured

To evaluate the safety of the infusion of inducible caspase 9 (BPZ-1001) modified T-cells followed by dimerizer drug, AP1903. Safety evaluated by number of participants with Adverse events.

Analysis population: Participant who received Donor Lymphocyte infusion and AP 1903

Groups in this outcome

Transplant Only

Participants who did not move forward to DLI

Transplat Plus DLI

Proceeded to DLI per protocol

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Transplant Only	0
Transplat Plus DLI	1

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Transplant Only	0	Not reported	Not reported	Not reported	Not reported
Transplat Plus DLI	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

calculate Pct

false

classes

categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1

denoms

counts
group Id
OG000
value
0
group Id
OG001
value
1
units
Participants

description

To evaluate the safety of the infusion of inducible caspase 9 (BPZ-1001) modified T-cells followed by dimerizer drug, AP1903. Safety evaluated by number of participants with Adverse events.

groups

description
Participants who did not move forward to DLI
id
OG000
title
Transplant Only
description
Proceeded to DLI per protocol
id
OG001
title
Transplat Plus DLI

param Type

COUNT_OF_PARTICIPANTS

population Description

Participant who received Donor Lymphocyte infusion and AP 1903

reporting Status

POSTED

time Frame

up to 3.5 years

title

To Evaluate the Safety of Donor Lymphocyte Infusion Followed by Dimerizer Drug, AP1903 by Number of Participants With Adverse Events.

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice